vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and GREENE COUNTY BANCORP INC (GCBC). Click either name above to swap in a different company.
GREENE COUNTY BANCORP INC is the larger business by last-quarter revenue ($22.2M vs $18.7M, roughly 1.2× CytomX Therapeutics, Inc.). GREENE COUNTY BANCORP INC runs the higher net margin — 46.3% vs -0.8%, a 47.2% gap on every dollar of revenue. On growth, GREENE COUNTY BANCORP INC posted the faster year-over-year revenue change (23.8% vs -25.7%). GREENE COUNTY BANCORP INC produced more free cash flow last quarter ($6.2M vs $-15.8M). Over the past eight quarters, GREENE COUNTY BANCORP INC's revenue compounded faster (18.9% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Bank of Greene County is an American federally-chartered savings bank headquartered in Catskill, NY. The bank's branches are located in the Upstate New York counties of Greene, Columbia, Albany, Ulster, and Rensselaer.
CTMX vs GCBC — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $22.2M |
| Net Profit | $-154.0K | $10.3M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 52.0% |
| Net Margin | -0.8% | 46.3% |
| Revenue YoY | -25.7% | 23.8% |
| Net Profit YoY | 97.6% | 37.4% |
| EPS (diluted) | — | $0.60 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $22.2M | ||
| Q3 25 | — | $21.5M | ||
| Q2 25 | $18.7M | $20.5M | ||
| Q1 25 | $50.9M | $20.1M | ||
| Q4 24 | $38.1M | $17.9M | ||
| Q3 24 | $33.4M | $16.9M | ||
| Q2 24 | $25.1M | $16.6M | ||
| Q1 24 | $41.5M | $15.7M |
| Q4 25 | — | $10.3M | ||
| Q3 25 | — | $8.9M | ||
| Q2 25 | $-154.0K | $9.3M | ||
| Q1 25 | $23.5M | $8.1M | ||
| Q4 24 | $18.9M | $7.5M | ||
| Q3 24 | $5.7M | $6.3M | ||
| Q2 24 | $-6.5M | $6.7M | ||
| Q1 24 | $13.8M | $5.9M |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | 47.4% | ||
| Q2 25 | -6.9% | 53.5% | ||
| Q1 25 | 44.4% | 44.6% | ||
| Q4 24 | 46.4% | 45.0% | ||
| Q3 24 | 12.3% | 39.6% | ||
| Q2 24 | -33.7% | 41.2% | ||
| Q1 24 | 28.1% | 39.4% |
| Q4 25 | — | 46.3% | ||
| Q3 25 | — | 41.2% | ||
| Q2 25 | -0.8% | 45.6% | ||
| Q1 25 | 46.2% | 40.1% | ||
| Q4 24 | 49.6% | 41.7% | ||
| Q3 24 | 17.2% | 37.1% | ||
| Q2 24 | -26.0% | 40.6% | ||
| Q1 24 | 33.3% | 37.3% |
| Q4 25 | — | $0.60 | ||
| Q3 25 | — | $0.52 | ||
| Q2 25 | — | $0.55 | ||
| Q1 25 | — | $0.47 | ||
| Q4 24 | — | $0.44 | ||
| Q3 24 | — | $0.37 | ||
| Q2 24 | — | $0.39 | ||
| Q1 24 | — | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $258.3M |
| Total Assets | $175.1M | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | $155.5M | ||
| Q4 24 | $38.1M | $166.4M | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | $190.4M | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $258.3M | ||
| Q3 25 | — | $248.2M | ||
| Q2 25 | $119.9M | $238.8M | ||
| Q1 25 | $25.0M | $229.0M | ||
| Q4 24 | $-456.0K | $218.4M | ||
| Q3 24 | $-23.5M | $216.3M | ||
| Q2 24 | $-31.2M | $206.0M | ||
| Q1 24 | $-31.7M | $199.2M |
| Q4 25 | — | $3.1B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | $175.1M | $3.0B | ||
| Q1 25 | $98.5M | $3.0B | ||
| Q4 24 | $120.5M | $3.0B | ||
| Q3 24 | $139.0M | $2.9B | ||
| Q2 24 | $159.2M | $2.8B | ||
| Q1 24 | $184.7M | $2.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $6.4M |
| Free Cash FlowOCF − Capex | $-15.8M | $6.2M |
| FCF MarginFCF / Revenue | -84.6% | 28.0% |
| Capex IntensityCapex / Revenue | 0.1% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 0.62× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $47.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.4M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | $-15.8M | $28.0M | ||
| Q1 25 | $-21.0M | $7.3M | ||
| Q4 24 | $-19.9M | $5.3M | ||
| Q3 24 | $-20.7M | $2.1M | ||
| Q2 24 | $-19.5M | $24.9M | ||
| Q1 24 | $-26.0M | $5.6M |
| Q4 25 | — | $6.2M | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | $-15.8M | $27.3M | ||
| Q1 25 | $-21.2M | $7.3M | ||
| Q4 24 | $-20.0M | $5.1M | ||
| Q3 24 | $-20.7M | $2.0M | ||
| Q2 24 | $-19.6M | $23.4M | ||
| Q1 24 | $-26.2M | $4.9M |
| Q4 25 | — | 28.0% | ||
| Q3 25 | — | 30.4% | ||
| Q2 25 | -84.6% | 133.3% | ||
| Q1 25 | -41.6% | 36.1% | ||
| Q4 24 | -52.5% | 28.6% | ||
| Q3 24 | -62.1% | 11.8% | ||
| Q2 24 | -78.2% | 141.2% | ||
| Q1 24 | -63.1% | 31.3% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | 0.1% | 3.4% | ||
| Q1 25 | 0.2% | 0.3% | ||
| Q4 24 | 0.2% | 1.0% | ||
| Q3 24 | 0.1% | 0.9% | ||
| Q2 24 | 0.4% | 9.1% | ||
| Q1 24 | 0.3% | 4.2% |
| Q4 25 | — | 0.62× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 3.00× | ||
| Q1 25 | -0.89× | 0.91× | ||
| Q4 24 | -1.05× | 0.71× | ||
| Q3 24 | -3.61× | 0.34× | ||
| Q2 24 | — | 3.70× | ||
| Q1 24 | -1.89× | 0.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
GCBC
Segment breakdown not available.
